SYK stock verdict - Avoid
SYK
Stryker Corporation
AVOIDHealthcare
$330.25
Fundamentals below bar
$330.25
Heavy$146.25Buy$177.59Fair$208.93Exit$229.82
FUNDAMENTAL53
TECHNICAL65
TRUST SCORE
100High
confidence in this read — data completeness, earnings quality & coverage
Uptrend · EMA20 319.92 · EMA50 318.53 · EMA200 338.23 · RSI 56.3 · MACD below signal
PROS
- Revenue grew 10.8%/yr on average over the last 3 years
- TTM EPS grew 16.5% year-over-year
- Converts 18% of revenue into free cash flow
- High gross margin of 64% (3-yr avg)
- Price is in an uptrend — above key moving averages with positive momentum
CONS
- Trades above the model's exit level ($229.82) — overvalued on this framework
- Expensive on trailing earnings (P/E 38.3×)
✳ Pros and cons are machine-generated from the latest fundamentals and technicals.
EARNINGS QUALITY · we check the accounting so you don't have to
✓Operating cash flow is 155% of net income — profit is backed by real cash
✓Low accruals — reported profit tracks the cash actually generated
✓Receivables growing in line with sales
SECTOR PEERS
Analysis as of 2026-07-27 · price live, fundamentals from latest filings
FAQ
Why is SYK rated Avoid?
SYK (Stryker Corporation) is rated Avoid because the model combines fundamentals, price action, and earnings-quality checks. The current signal is Fundamentals below bar. Revenue grew 10.8%/yr on average over the last 3 years and TTM EPS grew 16.5% year-over-year
Is SYK overvalued right now?
SYK is trading at $330.25 versus an estimated fair value of $208.93. That puts the stock in avoid territory on this framework. Trades above the model's exit level ($229.82) — overvalued on this framework and Expensive on trailing earnings (P/E 38.3×)
What should I watch before acting on SYK?
Watch the trust score of 100, the earnings-quality checks, and any red flags. Trades above the model's exit level ($229.82) — overvalued on this framework and Expensive on trailing earnings (P/E 38.3×)